RESUMO
Entre el 15 y el 17 del pasado mes de mayo de 2021 se llevó a cabo un nuevo congreso virtual del American College of Cardiology, uno de los eventos científicos más esperados de la cardiología mundial. Se contó con expositores de excelente nivel y la presentación de trabajos destacados que han realizado un aporte significativo a nuestra práctica clínica referidos a un gran abanico de situaciones frecuentes: cirugía cardíaca, cardiología intervencionista, manejo de arritmias. A continuación, seleccionamos y resumimos algunos de los trabajos más significativos: Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM). TicAgrelor versus CLOpidogrel in Stabilized Patients with Acute Myocardial Infarction (TALOS-AMI). Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke III (LAAOS III). Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure (SOLOIST-WHF). A Randomized Ablation-based atrial Fibrillation rhythm control versus rate control Trial in patients with heart failure and high burden Atrial Fibrillation (RAFT-AF). Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE).
Summary: The Annual meeting of the American Cardiology College Congress was held virtually between 15th and 17th of May in present 2021. This is indeed one of the most expected and relevant scientific events in the world of Cardiology. We had excellent speakers and outstanding presentations updating central themes in our clinical practice referring to a wide range of frequent situations such us: cardiac surgery, interventional cardiology, management of arrhythmias. Bellow, we select and summarize some of the most significant works: Aspirin versus clopidogrel for chronic maintenance monotherapy after percutaneous coronary intervention (HOST-EXAM). TicAgrelor versus CLOpidogrel in Stabilized Patients with Acute Myocardial Infarction (TALOS-AMI). Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke III (LAAOS III). Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure (SOLOIST-WHF). A Randomized Ablation-based atrial Fibrillation rhythm control versus rate control Trial in patients with heart failure and high burden Atrial Fibrillation (RAFT-AF). Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE).
De 15 a 17 de maio de 2021, foi realizada uma nova reunião virtual do congresso anual do American College of Cardiology, um dos eventos científicos mais relevantes do mundo da cardiologia. Houve excelentes palestrantes e a apresentação de estudos notáveis ââque atualizaram temas centrais em nossa prática clínica referentes a uma ampla gama de situações comuns: cirurgia cardíaca, cardiologia intervencionista, manejo de arritmias. A seguir, selecionamos e resumimos algumas das obras mais significativas: Aspirina versus clopidogrel para monoterapia de manutenção crônica após intervenção coronária percutânea (EXAME-HOST). TicAgrelor versus CLOpidogrel em pacientes estabilizados com infarto agudo do miocárdio (TALOS-AMI). Oclusão do apêndice atrial esquerdo durante a cirurgia cardíaca para prevenir acidente vascular cerebral III (LAAOS III). Sotagliflozina em pacientes com diabetes e insuficiência cardíaca recente (SOLOIST-WHF). Um ensaio randomizado de controle de ritmo de fibrilação atrial baseado em ablação versus controle de frequência em pacientes com insuficiência cardíaca e fibrilação atrial de alta carga (RAFT-AF). Dosagem de aspirina: um estudo centrado no paciente que avalia os benefícios e eficácia a longo prazo (ADAPTÁVEL).
RESUMO
Resumen: La necesidad de distanciamiento social impuesta por la actual pandemia por coronavirus obligó a las diferentes sociedades científicas a realizar sus actividades en formato completamente virtual. La Sociedad Europea de Cardiología no ha sido la excepción. Desde el 29 de agosto al 1 de septiembre de 2020 se celebró este evento sin precedentes que, además de contar con 125.000 profesionales de 213 países, permitió el acceso gratuito a todos los cibernautas. De esta manera, la actualidad en cardiología pudo llegar a todos los rincones del mundo, pese a las circunstancias tan complejas. Como ya es tradición de la revista, realizamos un resumen de los principales ensayos presentados durante el congreso: - Early Rhythm-Control Therapy in Patients with Atrial Fibrillation (EAST-AFNET 4) - Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (The EMPEROR-Reduced Trial Investigators) - Efficacy and Safety of Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM) - Angiotensin Receptor Neprilysin Inhibition Compared with Individualized Medical Therapy for Comorbidities in Patients with Heart Failure and Preserved Ejection Fraction (The PARALLAX Trial) - A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (DAPA-CKD) - Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation (POPULAR TAVI (Cohort A)) - Colchicine in Patients with Chronic Coronary Disease (The LoDoCo2 Trial Investigators) - Pharmacological Blood Pressure-Lowering for Primary and Secondary Prevention of Cardiovascular Disease Across Different Levels of Blood Pressure (BPLTTC) - Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (The BRACE CORONA Trial) - Randomized Trial of Transfusion Strategies in Patients with Myocardial Infarction and Anemia (REALITY Trial)
Summary The need for social distancing imposed by the current coronavirus pandemic, forced the different scientific societies to carry out their activities in a completely virtual format. And the European Society of Cardiology has not been the exception. From August 29 to September 1 of 2020, this unprecedented event was held which, in addition to having 125,000 health professionals from 213 countries, allowed free access to all netizens. In this way, current affairs in cardiology could reach all corners of the world, despite such complex circumstances. As is the tradition of the magazine, we present a summary of the main essays presented during the congress: - Early Rhythm-Control Therapy in Patients with Atrial Fibrillation (EAST-AFNET 4) - Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (The EMPEROR-Reduced Trial Investigators) - Efficacy and Safety of Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM) - Angiotensin Receptor Neprilysin Inhibition Compared with Individualized Medical Therapy for Comorbidities in Patients with Heart Failure and Preserved Ejection Fraction (The PARALLAX Trial) - A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (DAPA-CKD) - Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation (POPULAR TAVI (Cohort A)) - Colchicine in Patients with Chronic Coronary Disease (The LoDoCo2 Trial Investigators) - Pharmacological Blood Pressure-Lowering for Primary and Secondary Prevention of Cardiovascular Disease Across Different Levels of Blood Pressure (BPLTTC) - Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (The BRACE CORONA Trial) - Randomized Trial of Transfusion Strategies in Patients with Myocardial Infarction and Anemia (REALITY Trial)
Resumo A necessidade de distanciamento social imposto pela atual pandemia do coronavírus, obrigou as diferentes sociedades científicas a desenvolverem suas atividades de forma totalmente virtual. E a Sociedade Europeia de Cardiologia não foi exceção. De 29 de agosto a 1º de setembro 2020, foi realizado esse evento inédito que, além de contar com 125.000 profissionais de saúde de 213 países, possibilitou o acesso gratuito a todos os internautas. Dessa forma, a atualidade da cardiologia pode atingir todos os cantos do mundo, apesar de circunstâncias tão complexas. Como é tradição da revista, apresentamos um resumo dos principais ensaios apresentados durante o congresso: - Early Rhythm-Control Therapy in Patients with Atrial Fibrillation (EAST-AFNET 4) - Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (The EMPEROR-Reduced Trial Investigators) - Efficacy and Safety of Mavacamten in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy (EXPLORER-HCM) - Angiotensin Receptor Neprilysin Inhibition Compared with Individualized Medical Therapy for Comorbidities in Patients with Heart Failure and Preserved Ejection Fraction (The PARALLAX Trial) - A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (DAPA-CKD) - Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation (POPULAR TAVI (Cohort A)) - Colchicine in Patients with Chronic Coronary Disease (The LoDoCo2 Trial Investigators) - Pharmacological Blood Pressure-Lowering for Primary and Secondary Prevention of Cardiovascular Disease Across Different Levels of Blood Pressure (BPLTTC) - Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (The BRACE CORONA Trial) - Randomized Trial of Transfusion Strategies in Patients with Myocardial Infarction and Anemia (REALITY Trial)
RESUMO
Resumen: La pandemia generada por el SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus) ha constituido un desafío mundial. En momentos de dificultad como los que se han presentado recientemente, es aún más necesaria la investigación para avanzar en el diagnóstico y tratamiento de las diferentes patologías. Utilizando el amplio desarrollo de los medios de comunicación, este año el Congreso del Colegio Americano de Cardiología (ACC por su sigla en inglés) se celebró del 28 al 30 de marzo en un formato virtual, permitiendo a profesionales de todo el mundo acceder a múltiples actividades científicas con el mismo nivel de excelencia que en las sesiones presenciales. Realizaremos un breve resumen de alguno de los principales trabajos científicos presentados: - Tailored Antiplatelet Initiation to Lessen Outcomes Due to Decreased Clopidogrel Response after Percutaneous Coronary Intervention: TAILOR-PCI. - Rivaroxaban in Peripheral Artery Disease after Revascularization: VOYAGER PAD trial. - Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction: VICTORIA Study Group. - The Evolut Low Risk Bicuspid Study. - PARTNER 3. Two-year clinical and echocardiographic outcomes. - Ticagrelor with and without Aspirin in Acute Coronary Syndrome After PCI: the TICO Trial - Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer: Caravaggio trial. - Ten-year Outcomes After Drug-eluting Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Disease: Extended Follow Up of the PRECOMBAT Trial. - Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation: POPular TAVI.
Summary The SARS-CoV-2 pandemic has been a global challenge. In times of difficulty such as those that have recently arisen, research is even more necessary to advance in the diagnosis and treatment of different pathologies. Using the extensive development of the media, this year the American Congress of Cardiology was held from March 28 to 30 in a virtual format, allowing professionals from around the world to access multiple scientific activities with the same level of excellence as in face-to-face sessions. We will make a brief summary of some of the main scientific papers presented: - Tailored Antiplatelet Initiation to Lessen Outcomes Due to Decreased Clopidogrel Response after Percutaneous Coronary Intervention: TAILOR-PCI. - Rivaroxaban in Peripheral Artery Disease after Revascularization: VOYAGER PAD trial:. - Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction: VICTORIA Study Group. - The Evolut Low Risk Bicuspid Study. - PARTNER 3. Two-year clinical and echocardiographic outcomes. - Ticagrelor with and without Aspirin in Acute Coronary Syndrome After PCI: the TICO Trial. - Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer: Caravaggio trial. - Ten-year Outcomes After Drug-eluting Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Disease: Extended Follow Up of the PRECOMBAT Trial. - Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation: POPular TAVI.
Resumo: A pandemia de SARS-CoV-2 tem sido um desafio global. Em tempos de dificuldade como os que surgiram recentemente, a pesquisa é ainda mais necessária para avançar no diagnóstico e tratamento de diferentes patologias. Utilizando o amplo desenvolvimento da mídia, este ano o Congresso Americano de Cardiologia foi realizado de 28 ao 30 de março em um formato virtual, permitindo que profissionais de todo o mundo acessassem diversas atividades científicas com o mesmo nível de excelência que nas sessões presenciais. Faremos um breve resumo de alguns dos principais trabalhos científicos apresentados: - Tailored Antiplatelet Initiation to Lessen Outcomes Due to Decreased Clopidogrel Response after Percutaneous Coronary Intervention: TAILOR - PCI. - Rivaroxaban in Peripheral Artery Disease after Revascularization: VOYAGER PAD trial. - Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction: VICTORIA Study Group. - The Evolut Low Risk Bicuspid Study. - PARTNER 3. Two-year clinical and echocardiographic outcomes. - Ticagrelor with and without Aspirin in Acute Coronary Syndrome After PCI: the TICO Trial. - Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer: Caravaggio trial. - Ten-year Outcomes After Drug-eluting Stents Versus Coronary Artery Bypass Grafting for Left Main Coronary Disease: Extended Follow Up of the PRECOMBAT Trial. - Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation: POPular TAVI.
RESUMO
Resumen: El infarto agudo de miocardio sin lesiones coronarias obstructivas (MINOCA) es una afección recientemente definida en la práctica cardiológica. Su diagnóstico se basa en la angiografía coronaria, que da inicio a un proceso de búsqueda etiológica muchas veces complejo, pero con importancia pronóstica y terapéutica. Existen diferentes mecanismos involucrados en los MINOCA, que se plantean una vez excluidas la embolia pulmonar, la miocarditis y el síndrome de takotsubo. Se reconoce un patrón epicárdico de MINOCA presente en los casos de disrupción de placa, disección, vasoespasmo, y, eventualmente, embolismo coronario; y un patrón microvascular en casos de espasmo microvascular y embolia coronaria de pequeños vasos. Varias herramientas son útiles en su estudio: ecocardiografía, ventriculografía izquierda, técnicas de imagen intravascular, estudio del flujo coronario y resonancia magnética cardíaca, entre otras. Su uso debe ser guiado por el juicio clínico, y si bien no hay un algoritmo claramente establecido, incorporar todas las herramientas disponibles puede determinar la causa definitiva en algunos pacientes. La presente revisión pretende acercar al cardiólogo clínico información útil para su práctica habitual.
Summary: Acute Myocardial Infarction with Non-Obstructive Coronary Arteries (MINOCA) is a recently defined condition in cardiology practice. The diagnosis starts with coronary angiography that is the beginning of an etiological research process, often complex, but with prognostic and therapeutic importance for each etiology. There are different mechanisms involved in MINOCA, which are posed once pulmonary embolism, myocarditis and takotsubo cardiomyopathy are excluded. It is described an epicardial pattern of MINOCA in cases of plaque disruption, dissection, vasospasm, and eventually coronary embolism; and a microvascular pattern in cases of microvascular spasm and small vessel coronary embolism. Several tools are useful in its study, such as echocardiography, left ventriculography, intravascular imaging techniques, study of coronary flow, and cardiac magnetic resonance, among others. Its use should be guided by clinical criteria. Despite there is no clearly established algorithm in our current practice, it is necessary to incorporate all available tools to approach the definitive MINOCA etiology whenever is possible. The aim of this review is to bring useful information to the clinical cardiologist for his daily practice.
Resumo: O Infarto Agudo do Miocárdio com Artérias Coronárias Não - Obstrutivas (MINOCA) é uma condição recentemente definida na prática cardiológica. O diagnóstico começa com a angiografia coronariana, que é o início de um processo de pesquisa etiológica, muitas vezes complexo, mas com importância prognóstica e terapêutica para cada etiologia. Existem diferentes mecanismos envolvidos no MINOCA, que são colocados uma vez que a embolia pulmonar, miocardite e cardiomiopatia de takotsubo são excluídos. É descrito um padrão epicárdico de MINOCA presente em casos de ruptura de placa, dissecção, vasoespasmo e embolia coronariana; e um padrão microvascular em casos de espasmo microvascular e embolia coronariana de pequenos vasos. Diversas ferramentas são úteis no estudo de MINOCA: ecocardiografia, ventriculografia esquerda, técnicas de imagem intravascular, estudo do fluxo coronariano, ressonância magnética cardíaca, entre outras. O uso destas deve ser guiado pela suspeita clínica e, embora não haja um processo claramente estabelecido em nossa prática atual, é necessário incorporar todas as ferramentas disponíveis para abordar a etiologia definitiva do MINOCA quando isso for possível. A presente revisão tem como objetivo fornecer ao cardiologista clínico informações úteis para sua prática usual.
RESUMO
Resumen: Del 16 al 18 de noviembre de 2019 se celebró en la ciudad de Philadelphia una nueva reunión del congreso anual del American College of Cardiology. Es uno de los eventos más relevantes de la cardiología mundial, y contó en esta oportunidad con la participación de destacados profesionales que presentaron los últimos ensayos clínicos en las sesiones de Late Breaking Science, abordando diferentes aspectos de la especialidad: estrategias innovadoras para reducir el riesgo cardiovascular, resultados de los ensayos de isquemia, controversias en el manejo contemporáneo de la estenosis aórtica, estado del arte del manejo de pacientes con síndromes coronarios agudos, desafíos en insuficiencia cardíaca y nuevas fronteras en la terapia lipídica. A continuación presentamos un resumen de los principales trabajos presentados: - The Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure Trial (DAPA-HF). - The COLchicine Cardiovascular Outcomes Trial (COLCOT). - Global Comparison of a Rivaroxaban-Based Antithrombotic Strategy versus an Antiplatelet-Based Strategy After Transcathether Aortic Replacement to Optimize Clinical Outcomes (GALILEO) Trial: Primary Results. - RECOVERY: Early Surgery versus Conventional Management for Asymptomatic Severe Aortic Stenosis. - International Study of Comparative Health Effectiveness With Medical and Invasive Approaches: Primary Report of Clinical Outcomes (ISCHEMIA).
Summary: A new meeting of the annual congress of the American College of Cardiology, was held from November 16 to 18 last year; located in the city of Philadelphia. As one of the most important events in global cardiology, it was attended by leading professionals who were the last clinical trials in the Late Breaking Science sessions, which addressed different aspects of the specialty: innovative strategies to reduce cardiovascular risk, results of the trials of ischemia, controversies in the contemporary management of aortic stenosis, state of the art of the management of patients with acute coronary syndromes, challenges in heart failure and new frontiers in lipid therapy. We will make a brief summary of the main presented trials: - The Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure Trial (DAPA-HF). - The COLchicine Cardiovascular Outcomes Trial (COLCOT). - Global Comparison of a Rivaroxaban-Based Antithrombotic Strategy versus an Antiplatelet-Based Strategy After Transcathether Aortic Replacement to Optimize Clinical Outcomes (GALILEO) Trial: Primary Results. - RECOVERY: Early Surgery versus Conventional Management for Asymptomatic Severe Aortic Stenosis. - International Study of Comparative Health Effectiveness With Medical and Invasive Approaches: Primary Report of Clinical Outcomes (ISCHEMIA).
Resumo: Uma nova reunião do congresso anual do Colégio Americano de Cardiologia, foi realizada de 16 a 18 de novembro do ano passado; localizado na cidade de Filadélfia. Como um dos eventos mais importantes da cardiologia global, contou com a presença de profissionais líderes que apresentaram os últimos ensaios clínicos nas sessões de Late Breaking Science, que abordaram diferentes aspectos da especialidade: estratégias inovadoras para reduzir o risco cardiovascular, resultados dos ensaios de isquemia, controvérsias no tratamento contemporâneo da estenose aórtica, estado da arte do tratamento de pacientes com síndromes coronárias agudas, desafios na insuficiência cardíaca e novas fronteiras na terapia lipídica. Faremos um breve resumo dos principais trabalhos apresentados: - The Dapagliflozin and Prevention of Adverse-Outcomes in Heart Failure Trial (DAPA-HF). - The COLchicine Cardiovascular Outcomes Trial (COLCOT). - Global Comparison of a Rivaroxaban-Based Antithrombotic Strategy versus an Antiplatelet-Based Strategy After Transcathether Aortic Replacement to Optimize Clinical Outcomes (GALILEO) Trial: Primary Results. - RECOVERY: Early Surgery versus Conventional Management for Asymptomatic Severe Aortic Stenosis. - International Study of Comparative Health Effectiveness With Medical and Invasive Approaches: Primary Report of Clinical Outcomes (ISCHEMIA).
RESUMO
Resumen: El 35° Congreso Uruguayo de Cardiología tuvo lugar en Punta del Este, del 7 al 9 de noviembre. Como cada año, constituyó una oportunidad de actualización en diferentes áreas de la cardiología, contando con la participación de invitados nacionales e internacionales. Asimismo, se dio a conocer la actividad científica desarrollada por diferentes autores mediante la exposición de temas libres. A continuación, comentamos los siete artículos premiados por el Comité Científico. - Prevención de muerte súbita (PREMUDE) en jugadores de fútbol: 10 años de valoración precompetitiva. - Perfil clínico de la fibrilación auricular en el posoperatorio de cirugía cardíaca. - Protocolo de cardio-oncología para el seguimiento de pacientes con riesgo de disfunción ventricular por quimioterapia. - Implicancia del uso del score de calcio coronario en la re-estratificación del riesgo cardiovascular en prevención primaria. - Análisis de la morbimortalidad asociada a implante percutáneo de válvula aórtica: valor de variables clínicas y scores de riesgo a mediano plazo. - Anticoagulación en bioprótesis valvular aórtica. Ensayo clínico randomizado multicéntrico. - Strain global longitudinal del ventrículo izquierdo permite predecir mejoría funcional y sobrevida en pacientes con insuficiencia mitral severa asintomática y función normal. Metaanálisis.
Summary: The 35th Uruguayan Congress of Cardiology was held in Punta del Este in November 7th to 9th. As every year, it was an opportunity to update in different cardiovascular areas with participation of national and international guests. Scientific activity of different authors was also announced, through exposition of several articles. We will comment the seven awarded abstracts. - Sudden death prevention (PREMUDE) in soccer players: 10 years of pre-competitive assessment. - Clinical profile of atrial fibrillation in the postoperative period of cardiac surgery. - Cardio-oncology protocol for the follow-up of patients at risk of ventricular dysfunction due to chemotherapy. - Implication of the use of coronary calcium score in the re-stratification of cardiovascular risk in primary prevention. - Analysis of morbidity and mortality associated with percutaneous aortic valve implantation: value of clinical variables and medium-term risk scores. - Anticoagulation in aortic valve bioprosthesis. Multicenter randomized clinical trial. - Longitudinal global left ventricular strain allows prediction of functional improvement and survival in patients with severe asymptomatic mitral regurgitation and normal function. Meta-analysis.
Resumo: O 35º Congresso Uruguaio de Cardiologia, aconteceu em Punta del Este, de 7 a 9 de novembro. Como todos os anos, foi uma oportunidade de atualização em diferentes áreas cardiológicas, graças à experiência de convidados nacionais e internacionais. Também foi anunciada a atividade científica de diferentes serviços, através da exposição de vários artigos. Propomos comentar os sete artigos premiados. - Prevenção de morte súbita (PREMUDE) em jogadores de futebol: 10 anos de avaliação pré-competitiva. - Perfil clínico da fibrilação atrial no pós-operatório de cirurgia cardíaca. - Protocolo cardio-oncológico para acompanhamento de pacientes com risco de disfunção ventricular devido à quimioterapia. - Implicação do uso do escore de cálcio coronariano na ré estratificação do risco cardiovascular na prevenção primária. - Análise da morbimortalidade associada ao implante valvar aórtico percutâneo: valor de variáveis clínicas e escores de risco a médio prazo. - Anticoagulação na bioprótese valvar aórtica. Ensaio clínico randomizado multicêntrico. - O strain global longitudinal do ventrículo esquerdo permite predizer melhora funcional e sobrevida em pacientes com insuficiência mitral assintomática grave e função normal. Meta-análise.
RESUMO
Resumen: El Congreso Europeo de Cardiología constituye uno de los eventos más relevantes de la comunidad cardiológica mundial. Fue realizado entre el 31 de agosto y el 4 de setiembre en el corazón de París, siendo el tema central la salud cardiovascular global. Como es habitual, contó con la presencia de más de 30.000 profesionales y destacados invitados. Se presentaron actualizaciones de varias guías de práctica clínica e importantes trabajos científicos que sin duda impactarán en el tratamiento de los pacientes con patología cardiovascular. A continuación realizaremos un breve resumen de algunos de los trabajos presentados: - A trial to evaluate the effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin in patients with heart failure and reduced left ventricular ejection fraction: DAPA-HF - Complete revascularization with multivessel PCI for myocardial infarction: the COMPLETE Trial - Angiotensin-neprylysin inhibition in heart failure with preserved ejection fraction: the PARAGON-HF - Antithrombotic therapy for atrial fibrillation with stable coronary disease: the AFIRE Investigators - Ticagrelor or prasugrel in patients with acute coronary syndromes: the ISAR-REACT 5 Trial
Summary: The European Congress of Cardiology is one of the most relevant events of the world cardiology community. It was held from August 31 to September 4 in the heart of Paris, France, the central theme being global cardiovascular health. As usual, it was attended by more than 30,000 professionals and prominent guests. Updates of several clinical practice guides and important scientific papers were presented. These undoubtedly will impact in the treatment of patients with cardiovascular pathology. Below we present a brief summary of some of the trials presented: - A trial to evaluate the effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin in patients with heart failure and reduced left ventricular ejection fraction: DAPA-HF - Complete revascularization with multivessel PCI for myocardial infarction: the COMPLETE Trial - Angiotensin-neprylysin inhibition in heart failure with preserved ejection fraction: the PARAGON-HF - Antithrombotic therapy for atrial fibrillation with stable coronary disease: the AFIRE Investigators - Ticagrelor or prasugrel in patients with acute coronary syndromes: the ISAR-REACT 5 Trial
Sumário: O Congresso Europeu de Cardiologia é um dos eventos mais relevantes da comunidade mundial de cardiologia. Foi realizada de 31 de agosto ao 4 de setembro no coração de Paris, na França, o tema central foi a saúde cardiovascular global. Como sempre, participaram mais de 30.000 profissionais e convidados de destaque. Atualizações de vários guias de prática clínica e importantes artigos científicos foram apresentados que, sem dúvida, impactarão o tratamento de pacientes com patologia cardiovascular. Abaixo, faremos um breve resumo de alguns trials apresentados: - A trial to evaluate the effect of the sodium-glucose cotransporter 2 inhibitor dapagliflozin in patients with heart failure and reduced left ventricular ejection fraction: DAPA-HF - Complete revascularization with multivessel PCI for myocardial infarction: the COMPLETE Trial - Angiotensin-neprylysin inhibition in heart failure with preserved ejection fraction: the PARAGON-HF - Antithrombotic therapy for atrial fibrillation with stable coronary disease: the AFIRE Investigators - Ticagrelor or prasugrel in patients with acute coronary syndromes: the ISAR-REACT 5 Trial
RESUMO
Resumen: Como todos los años, en esta oportunidad se celebró el 68º Congreso del Colegio Americano de Cardiología (ACC, por su sigla en inglés) entre los días 16 y 18 de marzo en Nueva Orleans, Luisiana. Ambientado en la ciudad del Mardi Gras y el jazz, nuevamente convocó a la cardiología mundial para promover el conocimiento a través de la presentación de múltiples actividades científicas. Contó con la presencia de más de 16.000 asistentes y se recibieron 2.300 artículos, muchos de los cuales, sin duda, modificarán la práctica clínica actual. Cabe destacar, asimismo, la presentación de la Guía de Prevención Primaria de la Enfermedad Cardiovascular, donde resalta el casi total abandono del ácido acetilsalicílico en prevención primaria debido a la falta de beneficio neto. Realizaremos un breve resumen de algunos de los principales trabajos científicos presentados: - Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation - The AUGUSTUS Trial - Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients - The PARTNER 3 trial - The Safety and Efficacy of Femoral Access in STEMI: The SAFARI-STEMI Trial - One-Month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy versus Standard 12-Month Dual Antiplatelet Therapy With Clopidogrel After Drug-Eluting Stent Implantation. STOP-DAPT 2 Trial - Results of a Large-scale, App-based Study to Identify Atrial Fibrillation Using a Smartwatch: The Apple Heart Study
Summary: As every year, on this occasion the 68th Congress of the American College of Cardiology was held from March 16 to 18 in New Orleans, Louisiana. Set in the city of Mardi Gras and jazz, it once again called on global cardiology to promote knowledge through the presentation of multiple scientific activities. It counted with the presence of more than 16.000 attendees and 2.300 articles were received, many of which will undoubtedly modify the current clinical practice. It is also worth mentioning the presentation of the Primary Prevention of Cardiovascular Disease Guideline, which highlights the almost total discontinuation of acetylsalicylic acid in primary prevention due to the lack of net benefit. We will make a brief summary of some of the main scientific papers presented: - Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation - The AUGUSTUS Trial - Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients - The PARTNER 3 trial - The Safety and Efficacy of Femoral Access in STEMI: The SAFARI-STEMI Trial - One-Month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy versus Standard 12-Month Dual Antiplatelet Therapy With Clopidogrel After Drug-Eluting Stent Implantation. STOP-DAPT 2 Trial - Results of a Large-scale, App-based Study to Identify Atrial Fibrillation Using a Smartwatch: The Apple Heart Study
Resumo: Como todos os anos, nesta ocasião, o 68º Congresso do Colégio Americano de Cardiologia (ACC após sua sigla em inglês) foi realizado de 16 a 18 de março em Nova Orleans, Louisiana. Situado na cidade do Mardi Gras e jazz, mais uma vez convidou a cardiologia do mondo para promover o conhecimento através da apresentação de múltiplas atividades científicas. Contou com a presença de mais de 16.000 participantes e 2.300 artigos recebidos, muitos dos quais sem dúvida modificarão a prática clínica atual. Também vale ressaltar a apresentação da Diretriz para a Prevenção Primária de Doenças Cardiovasculares, que destaca o quase total abandono do ácido acetilsalicílico na prevenção primária devido à falta de benefício líquido. Faremos um breve resumo de alguns dos principais trabalhos científicos apresentados: - Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation - The AUGUSTUS Trial - Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients - The PARTNER 3 trial - The Safety and Efficacy of Femoral Access in STEMI: The SAFARI-STEMI Trial - One-Month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy versus Standard 12-Month Dual Antiplatelet Therapy With Clopidogrel After Drug-Eluting Stent Implantation. STOP-DAPT 2 Trial - Results of a Large-scale, App-based Study to Identify Atrial Fibrillation Using a Smartwatch: The Apple Heart Study
RESUMO
Resumen: El 34° Congreso Uruguayo de Cardiología, celebrado en Montevideo del 2 al 4 de diciembre del pasado año, nuevamente destacó por las excelentes presentaciones de los temas más relevantes del ámbito cardiológico, así como también por sus invitados de renombre, nacionales e internacionales. Acompañando el gran nivel del Congreso se expusieron 32 temas libres que abarcaron diferentes áreas de la cardiología de los cuales comentaremos cuatro trabajos premiados: - Riesgo de trombosis en bioprótesis aórtica y eventos clínicos según uso de anticoagulación. Metaanálisis de la evidencia actual. - Uso de NT-ProBNP como predictor de evolución en el posoperatorio de cirugía cardíaca. - Prevalencia de septal pouch en una cohorte derivada para ecocardiograma transesofágico. - Incidencia de troponina T ultrasensible en rango anormal y su correlación con la anatomía coronaria en pacientes en valoración por enfermedad coronaria estable.
Summary: The 34th Uruguayan Congress of Cardiology, celebrated last year in Montevideo from December 2nd to 4th, again stood out for the excellent presentations of the most relevant topics in the field of cardiology, as well as for its renowned national and international guests. Accompanying the great level of the Congress, 32 articles that covered different topics in the cardiological area were presented, of which we will comment four awarded: - Risk of thrombosis in aortic bioprosthesis and clinical events according to the use of anticoagulation. Meta-analysis of current evidence. - Use of NT-ProBNP as a predictor of evolution in the postoperative period of cardiac surgery. - Prevalence of septal pouch in a cohort derived for transesophageal echocardiography. - Incidence of ultrasensitive troponin T in abnormal range and its correlation with coronary anatomy in patients in assessment for stable coronary disease.
Resumo: O 34º Congresso Uruguaio de Cardiologia, realizado em Montevidéu entre os dias 2 e 4 de dezembro no ano passado, voltou a destacar-se pelas excelentes apresentações dos temas mais relevantes no campo da cardiologia, bem como por seus renomados convidados, nacionais e internacionais. Acompanhando o grande nível do Congresso, tinham 32 temas livres que cobriam diferentes áreas da cardiologia, dos quais comentaremos quatro artigos premiados: - Risco de trombose na bioprótese aórtica e eventos clínicos de acordo com o uso de anticoagulação. Meta-análise da evidência atual. - Uso de NT-ProBNP como preditor de evolução no pós-operatório de cirurgia cardíaca. - Prevalência de bolsa septal em uma coorte derivada para ecocardiografia transesofágica. - Incidência de troponina T ultrassensível em faixa anormal e sua correlação com a anatomia coronariana em pacientes em avaliação para doença coronariana estável.
RESUMO
Resumen: El Congreso Europeo de Cardiología se llevó a cabo en la ciudad de Múnich del 25 al 29 de agosto. Sin duda, uno de los eventos más importantes e innovadores de la comunidad cardiológica reunió a más de 32.000 profesionales, con destacados invitados internacionales y múltiples actividades científicas. Además de las tradicionales presentaciones de estudios, se inauguró un área de Salud Digital: Digital Health Area donde se llevaron a cabo sesiones continuas sobre E-Cardiology, con múltiples presentaciones de apps móviles, telemedicina y tecnología digital tanto para los profesionales como para la comunidad. Se presentaron las nuevas guías europeas sobre Hipertensión Arterial, tan esperadas luego del debate planteado en relación con las guías americanas en 2017. Las pautas europeas se mantendrán dentro del umbral de diagnóstico de 140/90 mmHg y se centrarán en mejorar las tasas de control a través de combinaciones iniciales de dos fármacos antihipertensivos para la mayoría de los pacientes. Realizaremos un breve resumen de algunos de los principales trabajos científicos presentados: - Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease: ARRIVE. - Coronary CT Angiography and 5-Year Risk of Myocardial Infarction: The SCOT-HEART Investigators. - Partial Oral Treatment of Endocarditis: POET. - Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: GLOBAL LEADERS. - One-Year Outcomes after PCI Strategies in Cardiogenic Shock: CULPRIT-SHOCK.
Summary: The European Congress of Cardiology was held at Munich from August 25th to 29th. Undoubtedly one of the most important and innovative events of the cardiology community, it brought together more than 32.000 professionals, with prominent international guests and multiple scientific activities. In addition to the traditional presentations of studies, ESC 2018 inaugurated a: Digital Health Area, where continuous sessions on E-Cardiology were held with multiple presentations of mobile apps, telemedicine and digital technology for both, the professionals and the community. The new european guidelines on Arterial Hypertension, awaited after the discussion related with the American guidelines in 2017, were presented. European blood pressure guidelines will stick with the 140/90 mmHg diagnostic threshold and will focus on improving control rates through initial two-drug antihypertensive combinations for most patients. We will make a brief summary of some of the main scientific trials presented: - Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease: ARRIVE. - Coronary CT Angiography and 5-Year Risk of Myocardial Infarction: The SCOT-HEART Investigators. - Partial Oral Treatment of Endocarditis: POET. - Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: GLOBAL LEADERS. - One-Year Outcomes after PCI Strategies in Cardiogenic Shock: CULPRIT-SHOCK